CatalYm
PrivateLast Round
Series D
Jul 16, 2024
Total Funding Raised
$265.94M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
CatalYm is a biopharmaceutical company that develops proprietary immunotherapies designed to overcome cancer resistance to existing oncology treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CatalYm Comparables
Compare CatalYm with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LG Chem | 78% | |
| Nanjing Leads Biolabs Co Ltd | 77% | |
| AstraZeneca | 74% |
CatalYm Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jul 16, 2024 | ||||
| Series C | Nov 22, 2022 | ||||
| Series B | Nov 10, 2020 | ||||
| Seed | Aug 1, 2016 |
Key People
Founding team and executive leadership
CatalYm Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series A, Series D, Series C |
| Omega Funds | Series D |
| Forbion | Series D, Series C, Series B, Series A, Seed |
| Gilde Healthcare | Series D |
| Vesalius Biocapital Partners | Series D, Series C, Series B |
| Wachstumsfonds Bayern | Series B |
| Canaan Partners | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors increased 931% MoM, from 712 to 7.3K.
- Oct 1, 2025
Lead antibody visugromab advances to Phase 2b studies for solid tumors.
CatalYm Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about CatalYm's valuation, stock price, and market status.
Is CatalYm a public or private company?
CatalYm is a private company.
What is the current stock price of CatalYm?
CatalYm is a private company, so its shares have no public market price. Caplight tracks CatalYm's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CatalYm worth (valuation)?
Valuation information for CatalYm is not publicly available.
Can I buy CatalYm stock?
CatalYm shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CatalYm's last funding round?
CatalYm's most recent funding round was Series D on July 16, 2024.
Who are the main investors in CatalYm?
Key investors in CatalYm include Forbion Capital Partners, Vesalius Biocapital Partners, Canaan Partners, Bioqube Ventures, Jeito Capital.
Will CatalYm IPO soon?
No public IPO plans have been announced for CatalYm.
How can I track CatalYm secondary market activity?
Caplight tracks bids, offers, and trades in CatalYm's shares on secondary markets.